A Polarizing Case of Elevated Liver Enzymes
Brian C. Davis, Bryce S. Hartfield, Melissa Contos, Michael O. Idowu, R. Todd Stravitz – 8 April 2020
Reply
Manoj Kumar – 8 April 2020
Ritonavir and Lopinavir Suppress RCE1 and CAAX Rab Proteins Sensitizing the Liver to Organelle Stress and Injury
Atousa Khalatbari, Pratibha Mishra, Hui Han, Yuxin He, Michelle MacVeigh‐Aloni, Cheng Ji – 8 April 2020 – Organelle stress and Liver injuries often occur in human immunodeficiency virus (HIV) infected patients under anti‐HIV therapies, yet few molecular off‐targets of anti‐HIV drugs have been identified in the liver. Here, we found through total RNA sequencing that the transcription of a host protease Ras converting CAAX endopeptidase 1 (RCE1) was altered in HepG2 cells treated with anti‐HIV protease inhibitors, ritonavir and lopinavir.
A Polarizing Case of Elevated Liver Enzymes
Brian C. Davis, Bryce S. Hartfield, Melissa Contos, Michael O. Idowu, R. Todd Stravitz – 8 April 2020
Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation
Marina Serper, Ethan M. Weinberg, Jordana B. Cohen, Peter P. Reese, Tamar H. Taddei, David E. Kaplan – 8 April 2020
Letter to the Editor: Thromboelastography‐Guided Blood Product Transfusion in Cirrhosis With Coagulopathy: Real Saving or Just Less Waste?
Massimo Primignani, Giulia Tosetti, Armando Tripodi – 8 April 2020
E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice
Eva Moreno, Mathilda J.M. Toussaint, Saskia C. Essen, Laura Bongiovanni, Elsbeth A. Liere, Mirjam H. Koster, Ruixue Yuan, Jan M. Deursen, Bart Westendorp, Alain Bruin – 7 April 2020
COVID‐19 and liver disease
Jian Sun, Alessio Aghemo, Alejandro Forner, Luca Valenti – 6 April 2020
COVID‐19 and liver disease
Jian Sun, Alessio Aghemo, Alejandro Forner, Luca Valenti – 6 April 2020
Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance
Mark W. Douglas, Enoch S.E. Tay, Dao Sen Wang, Adrian T.L. Ong, Caroline Wilson, Amy Phu, Jen Kok, Dominic E. Dwyer, Rowena A. Bull, Andrew R. Lloyd, Tanya L. Applegate, Gregory J. Dore, Anita Y. Howe, Richard Harrigan, Jacob George – 6 April 2020 – Direct acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, but drug resistance could undermine proposed global elimination targets. Real‐world studies are needed to inform the impact of widespread DAA treatment on antiviral resistance in the community.